The Preclinical Testing Core (PTC) of the MODEL-AD) consortium supports preclinical screening of test compounds nominated by the greater research community. The PTC has established a streamlined preclinical drug testing strategy with go/no-go decision points that allow critical and unbiased assessments of potential therapeutic agents.

The PTC is accepting nominations for preclinical screening of test compounds in mouse models of late onset Alzheimer’s disease developed and validated by the disease-modeling project (DMP) of the MODEL-AD.  For more information see